Icahn on Genzyme manufacturing; Rid Pharma preps for trial in Bangladesh;

> Carl Icahn tells Forbes about the thinking leading up to his pre-Sanofi-acquisition play for Genzyme: "How broken is manufacturing? Could the FDA be so angry it would handicap Genzyme for years to come?" Article

> A drug court has outlined charges against five owners and officers of Rid Pharmaceuticals, accused of manufacturing adulterated paracetamol syrup linked to the deaths of 28 children in 2009. Story 

> Although pharmaceutical products are a "good little business," British chemical maker Yule Catto is open to selling its drug ingredient division. Article

> A wealthy Russian businessman and the Belarusian Belbiopharm group may join forces for the construction of an import-curbing pharma plant in Belarus. Story

> GSK has invested $4 million in a new plant in Sri Lanka to produce the OTC painkiller Panadol. Story

> While attempting to repair electrical service following a snow-induced roof collapse at First Boston Pharma, workers knocked a ladder into an electrical cabinet, sparking an explosion that started a fire. Story


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.